Caplin Point enters into strategic partnership with Canadian pharmaceutical company
Caplin Point, an Indian pharmaceutical company announced on Monday that the company has entered into a strategic partnership with a privately-owned Canadian pharmaceutical company, JAMP Pharma Group.
The agreement includes six injectable products to be filed shortly in Canada, of which, some of the products have already been filed by Caplin Steriles in the USA, a subsidiary of Caplin Point Laboratories Limited. Canada is one of the company’s key expansion areas in the regulated markets.
Caplin Point Laboratories Limited is engaged in the manufacturing of active pharmaceutical ingredients (APIs), finished formulations, research & development as well as clinical research. It also has a front-end generic presence in Latin America, brand marketing in Francophone Africa and an injectable facility approved by United States Food & Drug Administration (USFDA).
The company with its unique business model caters predominantly to emerging markets of Latin America and Africa, earning approximately 80 per cent of its revenue from Latin America and 20 per cent from the other markets.
At 12.27 pm today, its share was trading 0.81 per cent down at Rs 483.05. The share recorded an intraday high of Rs 503.00 and an intraday low of Rs 481.80 on BSE.